RZLT

Insider Trades

Name	Value	Action	Price	Current Price
Evans DaronCFO $29k10k shares BuyMar 30, 2026 $2.85 --
Roberts Brian KennethChief Medical Officer $48k28k shares BuyDec 16, 2025 $1.70 --
Hogenhuis WladimirDirector $9.5k5.7k shares BuyDec 16, 2025 $1.69 --
Evans DaronCFO $4.5k2.5k shares BuyDec 15, 2025 $1.79 --
Evans DaronCFO $4.5k2.5k shares BuyDec 15, 2025 $1.79 --
Karnawat Sunil RatilalChief Commercial Officer $160100 shares BuyDec 15, 2025 $1.60 --

News

globenewswire.comRezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Societyglobenewswire.comJun 17

zacks.comRZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?zacks.comJun 4

globenewswire.comRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Societyglobenewswire.comJun 4

benzinga.comRezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Studybenzinga.comJun 2

globenewswire.comRezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinismglobenewswire.comJun 2

Trade RZLT

About Rezolute, Inc.

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.

CEO: Nevan Charles Elam
IPO Date: Jan 14, 2013

Market Data

Open: $4.91
High: $5.16
Low: $4.88
Volume: 2.8M
Avg Volume: 2.1M
52W High: $11.46
52W Low: $1.07

Valuation

Market Cap: $483M
Enterprise Value: $473M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-69M
Revenue: $0
Net Income: $-74M
Cash: $94M
Debt: $1.6M

Events

EarningsSep 16

EPS est. -0.13